The purpose of this phase III, randomized, active control, parallel, non-inferiority, multicenter study is to verify the non-inferiority of peginterferon beta-1a produced by CinnaGen versus CinnoVex® (CinnaGen) in subjects with relapsing remitting multiple sclerosis (RRMS).
All the participants will receive one of the following regimens:
I. Pegylated interferon beta-1a (CinnaGen), autoinjector (Physioject™), 125mcg, subcutaneous, every 2 weeks for 24 months; II. Interferon beta-1a, CinnoVex® (CinnaGen), prefilled syringes, 30mcg, intramuscular, once a week for 24 months.
With the aim of ensuring the compliance and safety, in the first two months of the study, in each monthly visit, a trained expert nurse will be responsible for drug injection for both intervention groups and will train all patients for self-injection. By the end of the first two months to the end of the study, patients will self-inject the medication in both groups.
All other cares or medications will be allowed to continue by patients, except for disease modifying therapies (DMTs) and medicines which affect the immune system (e.g. immunosuppressants and immunomodulators). Any concomitant medication will be recorded for patients in their regular visits.
The primary objective of this study is to verify the non-inferiority of peginterferon beta-1a (CinnaGen) versus CinnoVex® (CinnaGen) in reducing the annualized relapse rate (ARR) in participants with relapsing remitting multiple sclerosis (RRMS) at 2 years.
The secondary objectives of this study are:
* Reducing the total number of new or newly enlarging T2 hyperintense lesions on brain magnetic resonance imaging (MRI) scans
* Slowing the progression of disability
* Comparing safety issues
Sample size:
Group sample sizes of 76 in the experimental group and 76 in the active comparator group will achieve almost 80% power to detect non-inferiority using a one-sided, two-sample t-test. The margin of non-inferiority is 0.17. The true ratio of the means at which the power is evaluated is 1.00. The significance level of the test is 0.05. The coefficients of variation of both groups are assumed to be 0.4. The dropout rate is assumed to be 10%; hence 168 patients will be randomized.
Sequence generation:
The randomization plan of the patients will be carried out centrally using Cran-R version 3.2.3. Using permuted block randomization, blocks (length of each block is 4 or 2) will be made, for a total of 168 patients with 1:1 allocation ratio. Once the randomization has been made, each patient is given a code with which he/she will be identified throughout the study. The assigned code will be made up of 3 numbers (corresponding to the randomization number) and by 4 initials (corresponding to the 2 first letter of the first name, the 2 first letter of the first surname) and 2 numbers (center code). The randomization number will be assigned in a consecutive way.
Blinding:
Because of the different routes of administration of drugs in the study groups, patient blinding is not possible.
Data management:
Principal investigator is responsible for safe keeping of all patients' records at all times. Original hard copies of case report forms (CRFs) will be sent to Clinical Trial Consultants (CTCs) upon request and at the end of the study for data management. A copy of the records will be kept at the center. Sending and receiving of all patients' documents will be made after taking into consideration safety and security issues.
Principal investigator should set necessary schemes to control the quality of:
* Drug delivery, storage and handling
* All clinical examinations
* Laboratory tests and other paraclinical investigations
* Patient care
Data monitoring:
The objectives of the data quality control (QC) are:
* To ensure the existence of the patients and the respect of ethics, including signed patient informed consent forms (ICFs)
* To identify the issues, including systematic issues, as early as possible for appropriate setting of action plans and corrective actions
* To ensure the validity of the data To meet these objectives, the possibility of the sites' QC must be explained to the investigators at the time of the study initiation and agreed by them. QC will be performed on sites by the Local Study Teams.
QC will be started after inclusion of 30% of patients and will be ended before 80% of inclusion.
Two levels of QC will be performed:
Quality of CRF completion: At the time of CRF reception, the Local Study Team will review the completed CRFs in order to assess the completeness and the quality of completion. The Local Study Team (monitor or designee) is responsible to set up an action plan in order to improve the quality at site level. In case of systematic issue, the Local Study Team will inform the Corporate Study Team.
Central database checks: In addition to the standard data management activities, the following parameters will be systematically assessed as a part of the QC of the study, in country- and site-levels by the Study Central Team:
* Signed ICFs
* Rates of error and missing data for the key variables
* Completion of the patients' questionnaire
* Enough clarity of the forms During the QC visit, the monitor will have to complete a QC visit report.
Principal investigators should set necessary schemes to control the quality of:
* Signed ICF
* Drug delivery, storage and handling
* All clinical examinations
* Laboratory tests and other paraclinical investigations
* Patient care
Research ethics approval:
* Ethics committee approval is mandatory for this study to commence.
* No patient will be recruited to this study without an informed consent.
* It will be made clear to all patients that they can leave the study any time they desire with no need for any explanation.
* To keep confidentiality in case of a lost document, the name and surname of the patients will not appear on evaluation forms.
* Adverse effect report forms will be processed after each visit. Research team is responsible for dealing with immediate aftermath of any adverse event regardless of whether or not the event is directly related to the medication that is being studied.
* All serious adverse events should be reported to DSMB (Data and Safety Monitoring Board). The board is responsible for making necessary decisions to deal with the situation. These decisions may include determining the relationship between the drug and the observed adverse event.
* The protocol, CRF, information for patients and informed consent forms will be submitted to the ethics committees responsible for the investigators in TUMS, for review and approval according to the national regulatory guidelines.
